Luxury skincare house developed a custom-lipidated Matrixyl variant from concept to launch in 16 weeks

Challenge

The luxury house's R&D group was repositioning its long-running collagen-support hero serum and wanted the active itself to be a brand-exclusive variant rather than off-the-shelf Palmitoyl Pentapeptide-4. The Head of R&D specified a custom lipid chain at the N-terminus designed for slower stratum-corneum partitioning, in-house compatibility data validated against the brand's existing oil-in-water emulsion carrier, and an exclusive supply arrangement so the variant wouldn't end up in a competitor's serum 18 months later. Most catalogue cosmetic-active vendors don't run custom-modified actives on this kind of timeline.

Approach

Pepoderma's R&D team confirmed the custom lipidation was within the routine SPPS scope of the cosmetic-grade facility and quoted a pilot synthesis at 200 g cosmetic-active scale. Pilot synthesis used standard Fmoc SPPS with the custom lipid coupled at the N-terminus before resin cleavage; the lot report covered HPLC at ≥99.0% measured purity, ESI-MS confirming the custom-lipidated mass, water content, counter-ion, and reference-aqueous-emulsion stability across 12 months. The supply agreement was structured as brand-exclusive for the variant for an agreed term, with bulk pricing scaled to forecast volume. Both the active and the variant's INCI registration were handled through Pepoderma's regulatory team in parallel with the pilot synthesis.

Outcome

Pilot lot landed in the R&D group's lab 8 weeks from signed brief, with bulk-scale production delivered at week 16. The custom-variant INCI registration cleared inside the production window. The repositioned hero serum launched on the brand's seasonal calendar with the brand-exclusive active named on pack and the on-pack claim supported by the documented stability data. The luxury house has since extended the exclusive supply agreement against a second-generation variant for an eye-area product.